Analysts Expect Kadmon Holdings Inc (NYSE:KDMN) Will Post Earnings of -$0.14 Per Share

Wall Street analysts expect Kadmon Holdings Inc (NYSE:KDMN) to post earnings per share (EPS) of ($0.14) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.13). Kadmon reported earnings of ($0.19) per share in the same quarter last year, which would indicate a positive year over year growth rate of 26.3%. The firm is expected to report its next earnings report on Monday, August 3rd.

On average, analysts expect that Kadmon will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.63) to ($0.58). For the next financial year, analysts anticipate that the business will report earnings of $0.34 per share, with EPS estimates ranging from ($0.62) to $2.97. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Kadmon.

Kadmon (NYSE:KDMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.05). The business had revenue of $6.74 million for the quarter, compared to analyst estimates of $0.38 million. Kadmon had a negative return on equity of 142.79% and a negative net margin of 813.33%.

KDMN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Thursday, June 4th. Oppenheimer restated a “buy” rating and issued a $8.00 price objective on shares of Kadmon in a report on Thursday, May 7th. Raymond James started coverage on Kadmon in a report on Tuesday, May 19th. They set an “outperform” rating and a $7.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Sunday. Finally, ValuEngine upgraded Kadmon from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Seven research analysts have rated the stock with a buy rating, Kadmon has an average rating of “Buy” and an average target price of $10.88.

Shares of NYSE:KDMN traded down $0.04 during trading hours on Wednesday, hitting $5.14. 79,709 shares of the company’s stock traded hands, compared to its average volume of 2,662,520. Kadmon has a 52 week low of $1.82 and a 52 week high of $5.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.40 and a current ratio of 6.42. The company’s fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $4.42. The company has a market cap of $844.96 million, a price-to-earnings ratio of -7.37 and a beta of 1.47.

A number of hedge funds have recently made changes to their positions in the stock. Aperio Group LLC increased its position in Kadmon by 14.8% in the first quarter. Aperio Group LLC now owns 18,971 shares of the company’s stock worth $79,000 after purchasing an additional 2,446 shares during the period. Principal Financial Group Inc. increased its position in Kadmon by 19.6% in the first quarter. Principal Financial Group Inc. now owns 20,207 shares of the company’s stock worth $85,000 after purchasing an additional 3,318 shares during the period. Amalgamated Bank increased its position in Kadmon by 16.1% in the fourth quarter. Amalgamated Bank now owns 27,270 shares of the company’s stock worth $124,000 after purchasing an additional 3,785 shares during the period. Meeder Asset Management Inc. increased its position in Kadmon by 49.1% in the fourth quarter. Meeder Asset Management Inc. now owns 14,843 shares of the company’s stock worth $68,000 after purchasing an additional 4,888 shares during the period. Finally, Horizon Kinetics Asset Management LLC increased its position in Kadmon by 6.1% in the first quarter. Horizon Kinetics Asset Management LLC now owns 89,733 shares of the company’s stock worth $376,000 after purchasing an additional 5,126 shares during the period. Hedge funds and other institutional investors own 85.64% of the company’s stock.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

See Also: volatile stocks

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.